ChemoCentryx said it has identified a novel drug candidate to treat inflammatory skin diseases.
The investigational new drug-coded CCX832 is an orally administered small molecule antagonist, which will undergo clinical development by early next year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
CCX832 is the fourth and final drug candidate under ChemoCentryx’s collaboration with GlaxoSmithKline (GSK), which triggered a $5m milestone payment by the latter.
With the acceptance of CCX832 by GSK, ChemoCentryx has delivered all four clinical development candidates as defined by the partners three and a half years ago.
